0001719406 false 0001719406 2022-07-18 2022-07-18 0001719406 NRXP:CommonStockParValue0.001PerShareMember 2022-07-18 2022-07-18 0001719406 NRXP:WarrantsToPurchaseOneShareOfCommonStockMember 2022-07-18 2022-07-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 18, 2022

NRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38302   82-2844431
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

1201 Orange Street, Suite 600

Wilmington, Delaware

  19801
(Address of principal executive offices)   (Zip Code)

 

(484) 254-6134
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.001 per share   NRXP   The Nasdaq Stock Market LLC
Warrants to purchase one share of Common Stock   NRXPW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

Appointment of Stephen Willard as Chief Executive Officer and Director

 

On July 18, 2022, NRx Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”), at which quorum was present and voting throughout. During the course of the Annual Meeting, the Company’s stockholders approved the two proposals listed below. The final results for the votes regarding each proposal are set forth in the following tables. Each of these proposals is described in detail in the Company’s Proxy Statement.

 

Proposal 1. The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending on December 31, 2022. The results of the voting were as follows:

 

Votes For   Votes Against   Abstentions
19,713,375   11,367,376   13,135,962

 

Proposal 2. The Company’s stockholders duly elected Chaim Hurvitz, by a plurality of votes cast, to serve as a Class I director until the 2025 Annual Meeting and until his successor is elected and qualified. The results of the voting were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
35,153,528   0   850,414   8,212,771

 

 

 2 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    NRX PHARMACEUTICALS, INC.  
       
Date: July 21, 2022 By: /s/ Michael Kunz  
    Name: Michael Kunz  
    Title:

Deputy General Counsel

 

 

 

 

 

 

 3